THE WOODLANDS, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2017. Financial Results Net ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

BANGALORE, Aug 17 (Reuters) - Repros Therapeutics Inc said it does not have enough cash to fund ongoing operations and a failure to raise cash in the immediate short term may result in the filing of ...

Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500 subject open label study as part of an FDA requirement for Androxal, and it's sent a "request for guidance" ...

THE WOODLANDS, Texas--(BUSINESS WIRE)--Sept. 18, 2006--Repros Therapeutics Inc. (NasdaqGM:RPRX) (PCX:RPRX) announced today that the Form S-3 shelf registration statement it filed on September 5, 2006 ...

NEW YORK, NY--(Marketwire - August 8, 2009) - The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of all purchasers of Repros Therapeutics, Inc. ("Repros") RPRX ...

THE WOODLANDS, Texas--(BUSINESS WIRE)--May 2, 2006--Zonagen, Inc. (Nasdaq:ZONA) (PCX:ZONA) today announced that it has effected its name change from Zonagen, Inc. to Repros Therapeutics Inc. The name ...

NEW YORK (AP) — Shares of Repros Therapeutics Inc. plunged 40 percent Monday after the company said that results from a study of its testosterone drug Androxal will be delayed because it is removing ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. After its most recent wild run, what does Wall Street have ...

Oct 7 (Reuters) - Repros Therapeutics Inc said its experimental drug Androxal restored normal sperm count while increasing testosterone levels in an exploratory study, sending its shares up nearly ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. In this ...